{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:35:54Z","timestamp":1786988154388,"version":"build-2736575974"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH-T1137809"],"award-info":[{"award-number":["TCVGH-T1137809"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CMRPD1P0151"],"award-info":[{"award-number":["CMRPD1P0151"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["BMRPC17"],"award-info":[{"award-number":["BMRPC17"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CMRPD1M0582"],"award-info":[{"award-number":["CMRPD1M0582"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031022","name":"Center for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["114-2320-B-182-021"],"award-info":[{"award-number":["114-2320-B-182-021"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["113-2320-B-182-021"],"award-info":[{"award-number":["113-2320-B-182-021"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejps.2025.107337","type":"journal-article","created":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T14:36:32Z","timestamp":1760884592000},"page":"107337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The fourth-generation EGFR tyrosine kinase inhibitor BLU-945 resensitizes ABCG2-overexpressing multidrug-resistant non-small cell lung cancer cells to cytotoxic anticancer drugs"],"prefix":"10.1016","volume":"215","author":[{"given":"Yen-Ching","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Huan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Shan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-Ho","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh.\u202fV.","family":"Ambudkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Pu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.ejps.2025.107337_bib0042","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1158\/1078-0432.CCR-18-0851","article-title":"Nilotinib as co-adjuvant treatment with doxorubicin in patients with sarcomas: a phase I trial of the Spanish Group for Research on Sarcoma","volume":"24","author":"Alemany","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ejps.2025.107337_bib0022","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1124\/jpet.103.063149","article-title":"ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins","volume":"310","author":"Bates","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2025.107337_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115716","article-title":"Tetrazole and oxadiazole derivatives as bioisosteres of tariquidar and elacridar: new potent P-gp modulators acting as MDR reversers","volume":"259","author":"Braconi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2025.107337_bib0020","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.ejmech.2019.06.066","article-title":"Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance","volume":"179","author":"Cai","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejps.2025.107337_bib0039","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1179\/1973947813Y.0000000147","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO)","volume":"26","author":"Cetin","year":"2014","journal-title":"J. Chemother."},{"issue":"21","key":"10.1016\/j.ejps.2025.107337_bib0032","doi-asserted-by":"crossref","first-page":"6577","DOI":"10.1016\/j.bmcl.2012.09.012","article-title":"Downregulation of mdr1 and abcg2 genes is a mechanism of inhibition of efflux pumps mediated by polymeric amphiphiles","volume":"22","author":"Cuestas","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.ejps.2025.107337_bib0046","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0022-3565(24)34974-2","article-title":"Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities","volume":"290","author":"Dantzig","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2025.107337_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100681","article-title":"Medicinal chemistry strategies to discover P-glycoprotein inhibitors: an update","volume":"49","author":"Dong","year":"2020","journal-title":"Drug Resist. Updat."},{"issue":"14","key":"10.1016\/j.ejps.2025.107337_bib0008","doi-asserted-by":"crossref","first-page":"9662","DOI":"10.1021\/acs.jmedchem.2c00704","article-title":"Discovery of BLU-945, a reversible, potent, and wild-type-sparing next-generation EGFR mutant inhibitor for treatment-resistant non-small-cell lung cancer","volume":"65","author":"Eno","year":"2022","journal-title":"J. Med. Chem."},{"issue":"26","key":"10.1016\/j.ejps.2025.107337_bib0038","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2025.107337_bib0024","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/978-1-60761-416-6_4","article-title":"Mechanisms of multidrug resistance in cancer","volume":"596","author":"Gillet","year":"2010","journal-title":"Methods Mol. Biol."},{"issue":"6","key":"10.1016\/j.ejps.2025.107337_bib0049","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1021\/mp200240a","article-title":"Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions","volume":"8","author":"Gillet","year":"2011","journal-title":"Mol. Pharm."},{"issue":"6","key":"10.1016\/j.ejps.2025.107337_bib0023","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1023\/A:1012866803188","article-title":"Overview: ABC transporters and human disease","volume":"33","author":"Gottesman","year":"2001","journal-title":"J. Bioenerg. Biomembr."},{"issue":"1","key":"10.1016\/j.ejps.2025.107337_bib0001","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"12 Pt 1","key":"10.1016\/j.ejps.2025.107337_bib0012","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1158\/1535-7163.MCT-07-0352","article-title":"New inhibitors of ABCG2 identified by high-throughput screening","volume":"6","author":"Henrich","year":"2007","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.ejps.2025.107337_bib0034","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1021\/acs.molpharmaceut.6b00249","article-title":"Osimertinib (AZD9291) attenuates the function of multidrug resistance-linked ATP-binding cassette transporter ABCB1 in vitro","volume":"13","author":"Hsiao","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2025.107337_bib0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.canlet.2019.01.001","article-title":"The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents","volume":"445","author":"Hsiao","year":"2019","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.ejps.2025.107337_bib0027","first-page":"2200","article-title":"Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia","volume":"39","author":"Inaba","year":"1979","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.ejps.2025.107337_bib0025","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/cn100078a","article-title":"The \"specific\" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP\/ABCG2)","volume":"2","author":"Kannan","year":"2011","journal-title":"ACS Chem. Neurosci."},{"issue":"4","key":"10.1016\/j.ejps.2025.107337_bib0029","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0928-0987(00)00114-7","article-title":"Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs","volume":"11","author":"Krishna","year":"2000","journal-title":"Eur. J. Pharm. Sci.: Off. J. Eur. Fed. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107337_bib0047","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.561936","article-title":"Clinical perspective of FDA approved drugs with P-glycoprotein inhibition activities for potential cancer therapeutics","volume":"10","author":"Lai","year":"2020","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.ejps.2025.107337_bib0051","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1158\/0008-5472.CAN-05-2915","article-title":"Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo","volume":"66","author":"Leggas","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2025.107337_bib0030","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drup.2016.05.001","article-title":"Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies","volume":"27","author":"Li","year":"2016","journal-title":"Drug Resist. Updat."},{"issue":"20","key":"10.1016\/j.ejps.2025.107337_bib0053","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1182\/blood-2010-09-304311","article-title":"Dismounting the MDR horse","volume":"116","author":"Libby","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2025.107337_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117542","article-title":"Epertinib counteracts multidrug resistance in cancer cells by antagonizing the drug efflux function of ABCB1 and ABCG2","volume":"180","author":"Lin","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"18","key":"10.1016\/j.ejps.2025.107337_bib0021","first-page":"4559","article-title":"Overexpression of the BCRP\/MXR\/ABCP gene in a topotecan-selected ovarian tumor cell line","volume":"59","author":"Maliepaard","year":"1999","journal-title":"Cancer Res."},{"issue":"15","key":"10.1016\/j.ejps.2025.107337_bib0040","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ejps.2025.107337_bib0033","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.bcp.2012.12.006","article-title":"The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms","volume":"85","author":"Natarajan","year":"2013","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejps.2025.107337_bib0004","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2008.07.014","article-title":"Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy","volume":"64","author":"Ota","year":"2009","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.ejps.2025.107337_bib0037","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1006\/bbrc.2001.5130","article-title":"Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells","volume":"285","author":"Ozvegy","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.ejps.2025.107337_bib0019","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2213437120","article-title":"Differential dynamics and direct interaction of bound ligands with lipids in multidrug transporter ABCG2","volume":"120","author":"Rasouli","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U S. A"},{"issue":"2","key":"10.1016\/j.ejps.2025.107337_bib0011","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0005-2736(01)00308-X","article-title":"A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2)","volume":"1512","author":"Robey","year":"2001","journal-title":"Biochim. Biophys. Acta"},{"issue":"10","key":"10.1016\/j.ejps.2025.107337_bib0010","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/sj.bjc.6601370","article-title":"Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity","volume":"89","author":"Robey","year":"2003","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.ejps.2025.107337_bib0017","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/0008-5472.CAN-03-3298","article-title":"Pheophorbide a is a specific probe for ABCG2 function and inhibition","volume":"64","author":"Robey","year":"2004","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.ejps.2025.107337_bib0002","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.ejps.2025.107337_bib0045","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1200\/JCO.1998.16.9.2964","article-title":"Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP","volume":"16","author":"Rowinsky","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.ejps.2025.107337_bib0044","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41568-023-00612-3","article-title":"Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters","volume":"23","author":"Sajid","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.ejps.2025.107337_bib0018","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1073\/pnas.97.6.2515","article-title":"Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein","volume":"97","author":"Sauna","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U S. A"},{"issue":"2","key":"10.1016\/j.ejps.2025.107337_bib0052","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1517\/17425255.4.2.205","article-title":"Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges","volume":"4","author":"Shukla","year":"2008","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"issue":"20","key":"10.1016\/j.ejps.2025.107337_bib0050","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1158\/0008-5472.CAN-04-0096","article-title":"Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice","volume":"64","author":"Stewart","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2025.107337_bib0043","article-title":"Beyond the boundary: the emerging roles of ATP-binding cassette transporters in multidrug resistance (MDR) and therapeutic targeting in cancer","volume":"84","author":"Sun","year":"2025","journal-title":"Drug Resist. Updat."},{"issue":"1","key":"10.1016\/j.ejps.2025.107337_bib0048","first-page":"209","article-title":"The controversial role of ABC transporters in clinical oncology","volume":"50","author":"Tamaki","year":"2011","journal-title":"Essays Biochem."},{"key":"10.1016\/j.ejps.2025.107337_bib0005","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3389\/fphar.2019.00208","article-title":"Inhibitors of Human ABCG2: from technical background to recent updates with clinical implications","volume":"10","author":"Toyoda","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejps.2025.107337_bib0028","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/0006-2952(93)90677-O","article-title":"Restricted transport of cyclosporin A across the blood-brain barrier by a multidrug transporter","volume":"46","author":"Tsuji","year":"1993","journal-title":"P-glycoprotein. Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejps.2025.107337_bib0026","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1124\/jpet.115.225482","article-title":"The inhibitor Ko143 is not specific for ABCG2","volume":"354","author":"Weidner","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.ejps.2025.107337_bib0036","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12943-018-0775-3","article-title":"Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells","volume":"17","author":"Wu","year":"2018","journal-title":"Mol. Cancer"},{"issue":"12","key":"10.1016\/j.ejps.2025.107337_bib0035","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1158\/1535-7163.MCT-07-2005","article-title":"Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter","volume":"6","author":"Wu","year":"2007","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.ejps.2025.107337_bib0013","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3390\/cancers12061366","article-title":"Erdafitinib resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs","volume":"12","author":"Wu","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejps.2025.107337_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114516","article-title":"The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs","volume":"188","author":"Wu","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107337_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.101011","article-title":"Perspectives on drug repurposing to overcome cancer multidrug resistance mediated by ABCB1 and ABCG2","volume":"71","author":"Wu","year":"2023","journal-title":"Drug Resist. Updat."},{"issue":"3","key":"10.1016\/j.ejps.2025.107337_bib0041","article-title":"Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis","volume":"8","author":"Yang","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ejps.2025.107337_bib0003","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1158\/1078-0432.CCR-0937-3","article-title":"Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer","volume":"10","author":"Yoh","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"24","key":"10.1016\/j.ejps.2025.107337_bib0009","doi-asserted-by":"crossref","first-page":"7837","DOI":"10.1021\/acs.jcim.3c01636","article-title":"Binding thermodynamics of fourth-generation EGFR inhibitors revealed by absolute Binding free energy calculations","volume":"63","author":"Zhou","year":"2023","journal-title":"J. Chem. Inf. Model."}],"updated-by":[{"DOI":"10.1016\/j.ejps.2025.107384","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000}},{"DOI":"10.1016\/j.ejps.2025.107384","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000}}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725003355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725003355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T04:16:36Z","timestamp":1780805796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098725003355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":53,"alternative-id":["S0928098725003355"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107337","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The fourth-generation EGFR tyrosine kinase inhibitor BLU-945 resensitizes ABCG2-overexpressing multidrug-resistant non-small cell lung cancer cells to cytotoxic anticancer drugs","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107337","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107337"}}